J 2023

Clinical pharmacy services in mental health in Europe: a commentary paper of the European Society of Clinical Pharmacy Special Interest Group on Mental Health

STUHEC, Matej, M. HAHN, Ivana TAŠKOVÁ, I. BAYRAKTAR, I. FITZGERALD et. al.

Basic information

Original name

Clinical pharmacy services in mental health in Europe: a commentary paper of the European Society of Clinical Pharmacy Special Interest Group on Mental Health

Authors

STUHEC, Matej (705 Slovenia), M. HAHN (276 Germany), Ivana TAŠKOVÁ (203 Czech Republic, belonging to the institution), I. BAYRAKTAR (792 Turkey), I. FITZGERALD (372 Ireland), L. MOLITSCHNIG (40 Austria), A. TATAREVIC (191 Croatia), N. LINDNER (40 Austria), L. AGNOLETTO (40 Austria) and F. DA COSTA (620 Portugal)

Edition

INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, NETHERLANDS, SPRINGER, 2023, 2210-7703

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

Netherlands

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 2.400 in 2022

RIV identification code

RIV/00216224:14160/23:00133605

Organization unit

Faculty of Pharmacy

DOI

UT WoS

001073897200001

Keywords in English

Clinical pharmacist interventions; Clinical pharmacy in mental health; European society of clinical pharmacy; Mental illnesses and pharmacy; Pharmaceutical services in mental health; Polypharmacy and clinical pharmacy; Psychotropics and clinical pharmacy

Tags

Tags

International impact, Reviewed
Změněno: 28/2/2024 07:22, Mgr. Daniela Černá

Abstract

V originále

A large proportion of the world's disease burden is attributable to mental illnesses. Although effective interventions are available, many patients still have limited access to evidence-based treatments. Aside from access, treatment gaps, including inappropriate medication selection and monitoring, are also routinely recognised. Mental health clinical pharmacists can help address these gaps and enable patients to receive optimised pharmaceutical care, particularly appropriate medication selection and monitoring. The European Society of Clinical Pharmacy (ESCP) Special Interest Group on Mental Health was established to improve standardised service provision in mental health settings across Europe. The Special Interest Group identified significant barriers (predominantly associated with reimbursement and position within the multidisciplinary team) to effective pharmaceutical care amongst those with mental illnesses. This commentary presents recommendations to address these gaps through improved mental health clinical pharmacy service provision.